Oftidor (Dorzolamide Hydrochloride)

Dorzolamide blocks carbonic anhydrase enzymes in the ciliary body, which reduces the production of aqueous humor. With less fluid entering the anterior chamber, intra‑ocular pressure decreases, providing therapeutic benefit in glaucoma and related conditions.

The dosing regimen for Oftidor is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Typically, the medication is instilled as one or two drops per eye once or twice daily, but exact instructions must come from a qualified eye‑care professional.

Safety data for dorzolamide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the prescribing ophthalmologist in consultation with the patient.

To request Oftidor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Oftidor belongs to the carbonic anhydrase inhibitor class, whereas many other glaucoma drops are beta‑blockers, prostaglandin analogues, or alpha‑agonists. Dorzolamide offers a distinct mechanism by reducing aqueous‑humor production, and can be used alone or in combination with other classes for additive pressure‑lowering effects.

Oftidor should be stored at room temperature, below 25 °C, in its original container. Protect the solution from direct light and moisture, and keep the cap tightly closed when not in use to maintain stability.

Oftidor is applied topically to the eye as drops. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac, avoiding contact between the dropper tip and the eye or surrounding tissues.

Serious adverse events, though rare, can include persistent ocular inflammation, corneal edema or ulceration, and severe allergic reactions such as angio‑edema or anaphylaxis. Any sudden vision changes, pain, or intense redness should prompt immediate medical evaluation.

Patients with a known hypersensitivity to dorzolamide, other sulfonamides, or any component of the formulation should avoid using Oftidor. Caution is also advised for individuals with severe renal impairment or those already receiving systemic carbonic anhydrase inhibitors.